Leukocytes play an important role not only in the physiological processes of inflammation and wound healing, but also in the pathophysiological process of atherosclerosis. Integral to their role in these processes is the ability of these cells to participate in and regulate the molecular events leading to thrombin formation, which is supported by several observations. For example, there is an active fibroproliferative response [1] as well as fibrin deposition [2, 3] accompanying these processes. Furthermore, monocytes interact with vascular endothelium, platelets, and mesenchymal cells, all of which respond to thrombin. Thrombin promotes numerous cellular effects including chemotaxis, proliferation, cytokine release, and extracellular matrix turnover [4] . Thus, it is likely that thrombin production at the leukocyte surface provides this important bioregulatory molecule at precise locations.
Typically, thrombin formation requires a series of zymogen to protease conversions catalyzed by select enzymatic complexes assembled on appropriate cellular membrane surfaces. Leukocytes, in particular monocytes, possess a variety of mechanisms to efficiently initiate and amplify thrombin generation at their membrane surface. Monocytes/macrophages actively regulate both the assembly and function, as well as the substrate specificity, of various coagulation enzymes through a variety of mechanisms including: the expression of membrane binding sites (receptors) for the various protein constituents of the complexes; the expression of different receptors, which may alter the function of the protease; and the expression of membrane proteases, which may induce cofactor and/or protease function. Monocyte stimulation with various agonists modulates many of these responses as does their adherence to, and differentiation on, various substrates [5] [6] [7] [8] [9] [10] [11] .
The role of monocytes/macrophages in tissue factor/factor VIIa-catalyzed initiation of blood coagulation Monocytes appear to be unique among cells in that they can provide the appropriate membrane surface for the assembly and function of all the coagulation complexes involved in tissue factor-initiated thrombin production (Fig. 1) . They can be induced to synthesize and express tissue factor antigen at their membrane surface by bacterial lipopolysaccharide (LPS) and immune complexes [5] . In vitro, tissue factor expression by monocytes has been shown to be up-regulated by a number of (patho)physiological agonists, including, but not limited to, c-reactive protein [10] and interleukin-1 [6] , markers of inflammation, as well as following binding to activated platelets through P-selectin via their constitutive expression of P-selectin glycoprotein ligand-1 [11] . More recently, tissue factor has been observed on circulating peripheral blood leukocytes [12] . Most of the cell surface tissue factor is latent or encrypted ($80-90%) expressing little or no procoagulant activity [13] . Cell lysis [14] or cell treatment with calcium ionophore [15] substantially increase monocyte tissue factor activity, which is probably a result of an increased availability of anionic phospholipids on the cell surface [15] , and not release from intracellular stores [16] .
Tissue factor-positive microparticles, derived from leukocytes, have also been observed in peripheral blood [12, 17] . These microparticles express P-selectin glycoprotein ligand-1 that binds to P-selectin expressed by activated platelets or platelet-derived microparticles [18] [19] [20] . This interaction results in the de-encryption of tissue factor and the formation of particles that can both initiate and propagate coagulant events at sites of vascular injury and developing thrombi [17, 19, 21] . These combined observations suggest that blood-borne tissue factor, either expressed by or released by leukocytes, may be involved in thrombus production at sites of vascular injury [17, [19] [20] [21] .
Tissue factor binds the plasma serine protease factor (F)VIIa and effects the proteolytic activation of FX to FXa [22] , and FIX to FIXa [23] , thereby initiating the extrinsic pathway of coagulation. The conditions under which either substrate is preferred are unknown. The coagulant response is propagated subsequently through the assembly and function of prothrombinase [24, 25] , a 1 : 1 Ca 2þ -dependent, stoichiometric complex of FVa and FXa, resulting in thrombin production at the monocyte surface. Table 1 summarizes the kinetic and functional constants governing prothrombinase assembly and function on leukocytes as compared to platelets. Monocytes express $ 16 000 prothrombinase binding sites per cell (apparent
, and activating prothrombin with a k cat % 34 s À1 (Table 1 ) [24] .
Prothrombinase assembly and function on the monocyte surface, can be amplified by LPS [8] , which also stimulates monocyte expression of tissue factor. Analyses of the kinetics of prothrombin activation indicate that LPS stimulation of monocytes leads to a significantly increased (1.5-2.5-fold) cellular capacity to bind FVa and FXa [8] . Similar to what has been observed for tissue factor, increased expression of prothrombinase binding sites is due, in part, to LPS-stimulated protein synthesis since monocyte treatment with cycloheximide prior to LPS addition significantly decreases cell-associated prothrombinase activity [8] .
Prothrombinase assembly can also be amplified by processes inherent to the unstimulated monocyte (Fig. 1) . The FXa generated via prothrombinase not only can activate FV to FVa [26] , but also activates FVIII to FVIIIa to facilitate a FVIIIa/FIXa functional interaction with the monocyte surface to assemble intrinsic tenase, and activate additional FX to FXa [27] . Intrinsic tenase is defined by a 1 : 1 Ca 2þ -dependent, stoichiometric complex of cofactor and enzyme, expressing a k cat % 21 s
À1
, which is identical to that expressed by activated platelets [27, 28] . Interestingly, FX activation via monocyte intrinsic tenase is 25 times more efficient than its activation via a tissue factor/FVIIa complex, based on differences in both substrate turnover and the K m for the substrate [27] . Furthermore, the ability of monocytes to assemble intrinsic tenase is critical for sustained thrombin generation at the monocyte surface since functional tissue factor activity can be inhibited through the monocyte's coexpression of tissue factor pathway inhibitor [29] . Tissue factor pathway inhibitor virtually inactivates the entire extrinsic pathway initiating complex once FXa is formed [30, 31] .
The assembly and function of prothrombinase appears to be facilitated/amplified by several mechanisms unique to monocytes (Fig. 1) . Monocytes constitutively express membranebound forms of elastase and cathepsin G, which appear to be resistant to plasma protease inhibitors, that activate FV to FVa [32] . The cofactor activity generated remains bound to the membrane such that subsequent to FXa formation a fully functional prothrombinase complex is formed at the monocyte surface. Furthermore, FVa bound to monocytes (even in the absence of FXa) is protected from inactivation by activated protein C suggesting that cofactor activity is sustained on the cell surface, and furthermore that monocytes are unable to effectively down-regulate prothrombinase [33, 34] .
Regulation of prothrombinase activity on the monocyte membrane surface is effected further by the various extracellular matrix proteins to which they are bound [9] . Collagen I, collagen IV and fibronectin matrices support monocyte adherence nearly equivalently, whereas laminin supports monocyte adherence at a level %10-15% of that observed with the other substrates. However, laminin appears to select for a population of monocytes that are more procoagulant expressing a prothrombinase activity that is three to five times higher on a per cell basis when compared to monocytes bound to the other substrates. Furthermore, continued culture of monocytes on laminin results in a cell population that expresses a 10-to 40-fold increase in the rate of thrombin generation via prothrombinase [9] . These data are consistent with observations that human monocytes/macrophages display a great degree of phenotypic heterogeneity due in large part to the environment to which they are exposed [35, 36] . Furthermore, their adherence to basement membrane components is of considerable importance in the pathogenesis of atherosclerosis [37] . This notion is further supported by several studies that indicate that the differentiation of monocytes into macrophages further alters their procoagulant potential. Maturation of rabbit and human alveolar macrophages in culture led to a two-to sixfold increase in the apparent V max for tissue FVIIa-catalyzed activation of FX without significant changes in the apparent K m or apparent K d for tissue factor binding to FVIIa [38] . Consistent with these observations, Meisel and colleagues recently demonstrated that tissue factor antigen and activity were significantly increased as a result of monocyte differentiation into macrophages [39] . Similar observations have been made regarding prothrombin activation (see 'Alternative pathways for initiation of blood coagulation at the monocyte/macrophage surface'). These combined data verify that the blood coagulation pathways operate efficiently to generate thrombin on the monocyte/ macrophage membrane. Thrombin, once generated, can bind to the monocyte membrane [40] and cleave bound fibrinogen [41, 42] to fibrin monomers [43] , which are subsequently cross-linked by a FXIIIa-like molecule released from these cells [44] .
Model systems defining the role of tissue factor-bearing cells in thrombin generation
The importance of tissue factor-bearing monocytes in the initiation of the coagulation response was demonstrated by Hoffman and colleagues using an in vitro model of blood coagulation that closely mimics in vivo conditions [45] [46] [47] [48] [49] [50] . In this model, blood coagulation events are assayed in the presence of monocytes stimulated to express tissue factor, and plasma concentrations of unactivated platelets, coagulation zymogens, and inhibitors. Tissue factor/FVIIa expressed on the monocyte surface mediates the generation of small amounts of FXa and FIXa [45] [46] [47] [48] . Following activation of FV to FVa by FXa [26] or monocyte-bound forms of cathepsin G and elastase [32] , thrombin is generated via the assembly of prothrombinase on the monocyte surface [45] [46] [47] [48] . Sufficient thrombin is formed to result in platelet activation [45] [46] [47] [48] . FIXa formed at the monocyte surface, in complex with FVIIIa on the activated platelet, generates additional FXa [45, 46, 48] , resulting in enhanced thrombin formation at the platelet surface [45, 46, 48] . Based on these combined data it was proposed that blood coagulation occurs in three overlapping stages: (i) initiation on a tissue factor bearing cell; (ii) amplification, in which platelets and coagulation cofactors are activated; and (iii) propagation, in which large amounts of thrombin are generated via prothrombinase on the activated platelet surface [50] .
Alternative pathways for initiation of blood coagulation at the monocyte/macrophage surface Considerable effort has been focused on elucidating additional pathways by which monocytes can initiate and propagate the procoagulant response. An alternative, sequential proteolytic cascade that also initiates coagulation at the monocyte membrane, in the absence of tissue factor, has been proposed [51, 52] , although it has not yet been confirmed by other laboratories. In this model, monocytes can bind FX (15 000 sites per cell,
) through Mac1 (CD11b/CD18) [53] , a leukocyte-restricted member of the b 2 integrin family of cellular adhesion receptors [54] , which has undergone profound conformational changes due to transient cell activation with ADP, chemoattractants or other inflammatory agonists [55, 56] . FX binding to Mac1 triggers the release of the enzyme cathepsin G from azurophil granules, which in a Ca 2þ -dependent reaction catalyzes the cleavage of FX at a novel Leu177-Leu178 peptide bond to form an active protease [52] . The cathepsin G-activated FXa remains associated with the monocyte surface through its interaction with a membrane receptor previously referred to as effector cell protease receptor-1 (EPR-1) [57] , a Ca 2þ -dependent FXa receptor shown to be expressed by select leukocyte subpopulations [57, 58] , as well as vascular endocthelial cells [59] , smooth muscle cells [59] , and platelets [60, 61] . Interestingly, the published EPR-1 cDNA [62] differs from the cDNA for survivin, an apoptosis inhibitor expressed in malignant cells, by only five nucleotide changes, six nucleotide insertions, and its reverse orientation [63] . Furthermore, Zaman and Conway were unable to detect the gene encoding EPR-1 in the human or mouse genome [64] . Thus, it remains to be determined if the original EPR-1 cDNA clones that were described [62] contain sequence errors. Monocytes express as many as 170 000 EPR-1 molecules/cell which bind FXa with a K d $ 10 nmol L À1 [57] . In the absence of membrane bound FVa, FXa bound to EPR-1 appears to cleave prothrombin to thrombin [57] , although at a rate significantly less than that catalyzed by monocyte-bound prothrombinase. Similarly, McGee and Rothberger demonstrated that rabbit alveolar macrophages expressed high-affinity FXa receptors (
) that mediate activation of plasma concentrations of prothrombin in the absence of added plasma FVa [65] . However, the rate of prothrombin activation expressed by these macrophages is 4-fold higher than that expressed by human peripheral blood monocytes saturated with exogenously added FVa [24, 25] . Inhibition studies using antiFV antibodies suggest that these FXa receptors are functionally and antigenically similar to plasma FV. A FXa-EPR-1 complex on monocytes can also generate FIX activation intermediates [66] . The role that EPR-1 plays in assembling prothrombinase on monocytes has not yet been assessed. Although the existence of EPR-1 is in dispute, these data support the idea that monocytes/macro-phages employ unique mechanisms to effect the procoagulant response.
As discussed previously, monocyte-associated cathepsin G, in addition to activating FX, will also activate FV to FVa [32] . Furthermore, rabbit alveolar macrophages at intermediate stages of maturation generated and released FV activity [67] . Thus, monocytes/macrophages may be able to initiate coagulation via limited proteolytic activation of Mac1-bound FX followed by assembly of a functional prothrombinase.
Mac1 also functions as an inducible and high affinity receptor for fibrinogen [41, 42] , in a reaction associated with increased fibrin deposition at the cell surface [41] . Like FX, the fibrinogen binding is not constitutive, but requires a transient state of receptor activation induced by agonists such as thrombin and ADP. This binding interaction influences subsequent leukocyte-endothelium interactions by allowing the bound fibrinogen to bind ICAM-1 expressed on endothelial cells [68, 69] . It also appears to enhance platelet-leukocyte interactions, as well, since Mac1-bound fibrinogen binds to activated platelets via a direct interaction with the integrin aIIbb3 [70] . Fibrin, one formed, may function to modulate the coagulation response by its ability to down-regulate LPS-induced tissue factor expression by monocytes [71] . Monocytes stimulated in the presence of a formed clot or purified fibrin express substantially less tissue factor then cells stimulated in the absence of fibrin. In this system, fibrin-induced down-regulation of tissue factor production by monocytes may be a means to limit excessive blood clotting events at the monocyte membrane surface. However, the relevance of these findings in vivo remains to be determined.
The role of neutrophils and lymphocytes in blood coagulation
As is apparent from the discussion thus far, the majority of studies defining leukocyte involvement in coagulation reactions have been done with monocytes. Few studies have been carried out with neutrophils and virtually none with lymphocytes. In contrast to monocytes, which express the thrombin receptor substrate PAR-1 [72] (Fig. 1) , neither lymphocytes nor neutrophils appear to respond to thrombin through expression of PAR-1 [72] . Furthermore, neither support the assembly and function of intrinsic tenase [27] . Prothrombinase assembles and functions on both isolated cell populations [24, 25] . Kinetics of prothrombin activation indicate that these cells participate in thrombin generation in a manner analogous to monocytes in that FVa and FXa form a 1 : 1 stoichiometric, Ca 2þ -dependent complex at their membrane surfaces. Neutrophils and lymphocytes express %8000 and 45 000 prothrombinase binding sites/ cell, respectively, governed by an apparent K d % 10 À10 mol L À1 (Table 1 ) [24] . Lymphocytes express an apparent K m (0.62 mmol L À1 ) that is similar to that expressed by monocytes and platelets. In contrast, the lymphocyte bound complexes generate thrombin at a considerably slower rate (8 s
À1
). Prothrombinase assembled on neutrophils expresses a catalytic efficiency that is nearly identical to that of monocytes (28 s À1 ). As is apparent from the previous discussion, neutrophils also express tissue factor [12, [73] [74] [75] and are known to form intimate cell/cell contacts with activated platelets [76, 77] and endothelial cells [78] [79] [80] . Furthermore, neutrophils may also modulate activation of blood coagulation through their production and release of reactive oxygen species [81] . Depending on the neutrophil concentration present, released neutrophil reactive oxygen species either positively or negatively regulate expression of tissue factor subsequent to monocyte stimulation by LPS. Thus, the various ways in which neutrophils may contribute to thrombin generation is beginning to be appreciated. Lymphocyte contributions remain virtually unknown.
